Human medicines European Public Assessment Report EPAR : Rilutek, riluzole, Revision: 17,

New Drug Approvals

Riluzole is a drug used to treat amyotrophic lateral sclerosis. It delays the onset ofventilator-dependence or tracheostomy in selected patients and may increase survival by approximately 3–5 months

It is marketed by Sanofi-Aventis with the brand name Rilutek.

read all at

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000109/human_med_001039.jsp&mid=WC0b01ac058001d124

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s